Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ningxia Eppen Biotech Co. Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct art units, indicating that the company's biotech innovations are being reviewed by different specialized groups. The involvement of 2 distinct art units for only 2 pending actions suggests a lack of procedural concentration in the current portfolio.
The portfolio involves 2 distinct examiners, with EPSTEIN, TODD MATTHEW identified as the busiest examiner. This examiner is responsible for 1 pending office action. Since there are 2 distinct examiners for 2 pending office actions, each matter requires a unique approach tailored to the individual examiner. The prosecution team must navigate the specific requirements of 2 distinct art units while addressing the feedback from 2 different examiners to resolve the 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EPSTEIN, TODD MATTHEW | 1 | 60.8% | +43.6% |
| EIX, EMILY FAY | 1 | 45.7% | +76.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270487 | RECOMBINANT STRAIN WITH MODIFIED GENE BBD29_11265 FOR PRODUCING L-GLUTAMIC ACID, AND METHOD FOR CONSTRUCTING THE SAME AND USE THEREOF | EIX, EMILY FAY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18870708 | NCgl2747 Gene Mutant and Use Thereof in Preparation of L-lysine | EPSTEIN, TODD MATTHEW | — |
| 18270487 | RECOMBINANT STRAIN WITH MODIFIED GENE BBD29_11265 FOR PRODUCING L-GLUTAMIC ACID, AND METHOD FOR CONSTRUCTING THE SAME AND USE THEREOF | EIX, EMILY FAY | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18870708 | NCgl2747 Gene Mutant and Use Thereof in Preparation of L-lysine | EPSTEIN, TODD MATTHEW | 1652 | §112 | Non-Final OA | — | Pending | Dec 02, 2024 |
| 18270487 | RECOMBINANT STRAIN WITH MODIFIED GENE BBD29_11265 FOR PRODUCING L-GLUTAMIC ACID, AND METHOD FOR CONSTRUCTING THE SAME AND USE THEREOF | EIX, EMILY FAY | 1653 | §102§112 | Final Rejection | — | Pending | Jun 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNingxia Eppen Biotech Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Todd Matthew Epstein has the most, with 1 of Ningxia Eppen Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
